La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Bionano Genomics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Bionano Genomics..

Bionano Genomics (NASDAQ:BNGO) Azioni, Catena delle Opzioni

Bionano Genomics

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

Bionano Genomics Inc

Needham analyst Laura Martin reiterates Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) with a Hold.

News

Reiteration

Analyst Ratings

PERI

Needham Reiterates Hold on Perion Network

Virgin Galactic Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares closed up 3.5% on Wednesday after the company reported a net loss of $75 million for the third quarter, lower than the $105 million net loss reported in the corresponding period last year owing to lower operating expenses.
What Happened: Branson&#8217;s spaceflight company&#8217;s total operating expenses fell to $82.1 million in the third quarter from $116 million in the corresponding quarter a year ago. However, revenue also fell to $0.4 million from $1.7 million last year owing to the pause in commercial spaceflights.
Virgin Galactic is now focussing its efforts on the production of the Delta Class spaceships. The new spaceships remain on track to enter commercial service in 2026, the company said.
Delta Class will&nbsp;<a href="https://www.benzinga.com/news/24/06/39247906/planes-just-cant-compete-elon-musk-boasts-rocket-booster-superiority-after-richard-bransons-virgin-g" target="_blank" rel="noreferrer noopener">replace the company's VSS Unity spaceplane</a>&nbsp;which had its last commercial flight in the second quarter. 
Announces At-The-Market Equity Program: Virgin Galactic on Wednesday also said that it entered into a sales agreement under which it may offer and sell shares of its common stock having an aggregate offering price of up to $300 million from time to time pursuant to an "at the market" program.
The proceeds from the program, it said, will be used to accelerate the development and production of its next-generation spaceflight fleet, including an additional carrier plane such as the company&#8217;s VMS Eve dual fuselage jet carrier aircraft and third and fourth Delta Class spaceships.
Price Action: Virgin Galactic shares closed up 3.5% on Wednesday at $7.12. The stock, however, is down by about 85% year-to-date, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="650" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15.jpeg" alt="" class="wp-image-634803" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15.jpeg 650w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15-300x208.jpeg 300w" sizes="(max-width: 650px) 100vw, 650px" /></figure>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41767169/spacex-completes-400th-successful-falcon-launch-to-date-but-will-miss-target-of-144-launches-in-2024" target="_blank" rel="noreferrer noopener">SpaceX Completes 400th Successful Falcon Launch To Date, But Will Miss Target Of 144 Launches In 2024, Says Company Exec</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

Tech

SPCE

Richard Branson's Spaceflight Startup Virgin Galactic Sees Stock Surge After Narrowing Q3 Losses, Announces $300M Stock Sale

Needham analyst Joshua Reilly maintains Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) with a Buy and raises the price target from $45 to $60.

Price Target

VERX

Needham Maintains Buy on Vertex, Raises Price Target to $60

Truist Securities analyst Greg Miller maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Hold and raises the price target from $4100 to $4700.

BKNG

Truist Securities Maintains Hold on Booking Holdings, Raises Price Target to $4700

Needham analyst James Ricchiuti maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and raises the price target from $27 to $31.

KRNT

Needham Maintains Buy on Kornit Digital, Raises Price Target to $31

B of A Securities analyst Julien Dumoulin-Smith maintains TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) with a Buy and lowers the price target from $7 to $4.

TPIC

B of A Securities Maintains Buy on TPI Composites, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

BEAM

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

B of A Securities analyst Dimple Gosa maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Buy and lowers the price target from $65 to $52.

B of A Securities Maintains Buy on NEXTracker, Lowers Price Target to $52

B of A Securities analyst Julien Dumoulin-Smith maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Buy and lowers the price target from $25 to $24.

FLNC

B of A Securities Maintains Buy on Fluence Energy, Lowers Price Target to $24

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and raises the price target from $17 to $21.

CLBT

Needham Maintains Buy on Cellebrite DI, Raises Price Target to $21

B of A Securities analyst Julien Dumoulin-Smith maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Underperform and lowers the price target from $72 to $62.

ENPH

B of A Securities Maintains Underperform on Enphase Energy, Lowers Price Target to $62

Needham analyst Gil Blum reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Hold.

FOLD

Needham Reiterates Hold on Amicus Therapeutics

B of A Securities analyst Julien Dumoulin-Smith maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Underperform and lowers the price target from $8 to $7.

B of A Securities Maintains Underperform on Bloom Energy, Lowers Price Target to $7

Piper Sandler analyst Patrick Moley reiterates MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Neutral and maintains $265 price target.

MKTX

Piper Sandler Reiterates Neutral on MarketAxess Holdings, Maintains $265 Price Target

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Hold.

SRDX

Needham Reiterates Hold on Surmodics

Amazon Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) CEO Andy Jassy has expressed his disdain for bureaucracy and announced plans to reduce managerial layers within the company
What Happened: In a company-wide meeting on Tuesday, Jassy outlined the company&#8217;s decision to cut down on&nbsp;the number of managers.
The&nbsp;move was aimed at speeding up decision-making processes and preserving Amazon&#8217;s unique culture, which Jassy believes is being stifled by excessive management layers, <a href="https://www.businessinsider.in/tech/news/in-an-all-hands-meeting-amazon-ceo-andy-jassy-tells-employees-why-he-wants-fewer-managers-i-hate-bureaucracy/articleshow/114996847.cms">reported</a> Business Insider, citing a recording of the meeting.
&#8220;The goal again is to&nbsp;allow us to have higher&nbsp;ownership and to move more&nbsp;quickly,&#8221; Jassy stated during the meeting.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/11/41702294/apple-begins-shifting-iphone-17-production-in-india-cooks-china-optimism-and-more-this-week-in-apple?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Begins Shifting iPhone 17 Production In India, Cook&#8217;s China Optimism, And More: This Week In Appleverse</a>
Amazon announced in September that it plans to increase the ratio of individual workers to managers by 15% by the end of the first quarter of 2025.
As part of this initiative, Amazon launched a &#8220;Bureaucracy&nbsp;Mailbox&#8221; last month, where employees&nbsp;can voice concerns about unnecessary processes or rules.
 Jassy revealed that over 150 suggestions received through this platform have already been acted upon.
&#8220;The reality is that the&nbsp;S team and I hate&nbsp;bureaucracy,&#8221; Jassy said, referring to&nbsp;Amazon&#8217;s&nbsp;senior leadership team. &#8220;One of the reasons I&#8217;m still at&nbsp;this company is because it&#8217;s&nbsp;not a political or bureaucratic&nbsp;place.&#8221;
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: For the third quarter of 2024, Amazon reported <a href="https://www.benzinga.com/news/earnings/24/10/41664778/amazon-q3-earnings-highlights-revenue-beat-eps-beat-q4-guidance-new-kindles-significantly-outperfor">net sales of $158.9 billion</a>, up 11% year-over-year, beating Street consensus estimates.
Operating income for the third quarter reached $17.4 billion, an increase from $11.2 billion in the same period last year. Amazon Web Services, or AWS, was the primary driver, contributing $10.4 billion in operating income, compared to $7 billion in the third quarter of the previous year.
Amazon has also been expanding its <a href="https://www.benzinga.com/markets/equities/24/11/41735903/meta-amazon-microsoft-partner-on-defense-ai-initiative">partnerships and initiatives</a>, including a collaboration with Meta Platforms Inc., Microsoft Corp., and others on a defense AI initiative.
However, the company has also faced internal challenges. Last month, AWS CEO Matt Garman defended the company's <a href="https://www.benzinga.com/news/24/10/41394784/amazon-aws-ceo-stands-firm-on-5-day-office-policy-opponents-can-head-for-the-exit-door-there-are-oth">contentious new five-day in-office policy</a>, suggesting that those who oppose it may consider other employment options.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41706934/how-to-master-ios-18s-control-center-tips-to-reset-and-customize-your-iphones-quick-access-hub?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Master iOS 18&#8217;s Control Center: Tips To Reset And Customize Your iPhone&#8217;s Quick Access Hub</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Wikimedia

Media

AMZN

Amazon's Andy Jassy Says 'I Hate Bureaucracy' As He Plans To Slash Managerial Layers: 'The Goal Again Is… To Move More Quickly'

Needham analyst James Ricchiuti reiterates iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) with a Hold.

IRBT

Needham Reiterates Hold on iRobot

Needham analyst Ryan Koontz reiterates Kaltura (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTR#NASDAQ">KLTR</a>) with a Buy and maintains $3 price target.

KLTR

Needham Reiterates Buy on Kaltura, Maintains $3 Price Target

Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Buy and maintains $151 price target.

PRAX

Needham Reiterates Buy on Praxis Precision Medicine, Maintains $151 Price Target

Needham analyst Bernie McTernan maintains Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) with a Buy and raises the price target from $6 to $7.

SGHC

Needham Maintains Buy on Super Group (SGHC), Raises Price Target to $7

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bionano Genomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bngo-stock-quote/">BNGO</a>) just reported results for the second quarter of 2024.<ul><li>Bionano Genomics reported earnings per share of -24 cents. This was above the analyst estimate for EPS of -42 cents.</li><li>The company reported revenue of $7.77 million.</li><li>This was 2.86% worse than the analyst estimate for revenue of $8.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bngo-stock-earnings-bionano-genomics-for-q2-of-2024/">BNGO Stock Earnings: Bionano Genomics Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BNGO Stock Earnings: Bionano Genomics Beats EPS, Misses Revenue for Q2 2024

Maxim Group analyst Jason McCarthy maintained a Hold rating on BioNano Genomics (BNGO – Research Report) yesterday. The company's shares closed tod...

Maxim Group Reaffirms Their Hold Rating on BioNano Genomics (BNGO)

Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)

BTIG analyst Mark Massaro has reiterated their bullish stance on BNGO stock, giving a Buy rating on August 8. Mark Massaro has given his Buy rating...

Buy Rating Affirmed for BioNano Genomics Amidst Operational Progress and Strategic Financial Planning

BioNano Genomics ( ($BNGO) ) just unveiled an announcement. Bionano Genomics, Inc. is undergoing a significant reorganization to cut costs and opti...

BioNano Genomics Restructures for Cost Efficiency and Cash Flow Optimization

BioNano Genomics (BNGO – Research Report) received a Hold rating and price target from BTIG analyst Mark Massaro today. The company's shares closed...

BTIG downgrades BioNano Genomics (BNGO) to a Hold

BTIG downgrades Bionano to Neutral after fourth workforce reduction

Bionano Genomics cuts Q3 revenue view to $6.5M-$6.8M from $7.9M-$8.9M

Bionano Genomics (BNGO) announced the publication in Blood Cancer Journal by a group of researchers at the Korea College of Medicine in South Korea...

Bionano Genomics announces publication outlining utility of OGM

BioNano Genomics ( ($BNGO) ) has shared an update. Bionano Genomics announced a $3 million registered direct offering involving the sale of nearly ...

BioNano Genomics Announces $3M Direct Offering Initiative

BNGO

Press Releases

Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference

Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting

Comments

Bionano Genomics

Bionano Genomics (BNGO) Opzioni

Bionano Genomics (NASDAQ:BNGO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO